Potentiation of anti-cancer treatment by modulators of energy metabolism

Current Pharmaceutical Biotechnology

Volumn 14, Issue 3, 2013, Pages 313-330

  Shoshan, Maria C ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer chemotherapy; Energy metabolism; Potentiation

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; COUMESTROL; CURCUMIN; DAIDZEIN; DEOXYGLUCOSE; DICHLOROACETIC ACID; DOCETAXEL; DOXORUBICIN; ESTRADIOL 3 METHYL ETHER; ETOMOXIR; GENISTEIN; GLUCOCORTICOID; IMATINIB; LACTATE DEHYDROGENASE; MELPHALAN; OXALIPLATIN; PACLITAXEL; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PICEATANNOL; POLYPHENOL; PREDNISOLONE; PYRUVIC ACID DERIVATIVE; REACTIVE OXYGEN METABOLITE; RESVERATROL; ROTENONE; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CHEMOTHERAPY; CELL METABOLISM; CHEMOPROPHYLAXIS; COLON CANCER; CYTOTOXICITY; DRUG POTENTIATION; ENERGY METABOLISM; GLYCOLYSIS; HUMAN; LOW DRUG DOSE; LYMPHATIC LEUKEMIA; MESOTHELIOMA; MYELOID LEUKEMIA; MYELOMA; NEOPLASM; NONHUMAN; OVARY CANCER; OXIDATIVE STRESS; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RESPIRATORY CHAIN;

ANIMALS; ANTINEOPLASTIC AGENTS; ENERGY METABOLISM; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84875359600     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201011314030007     Document Type: Article

References (224)

1. DeBerardinis, R. J.; Lum, J. J.; Hatzivassiliou, G.; Thompson, C. B., The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab., 2008, 7 (1), 11-20.
2. Dang, C. V., Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res., 2010, 70 (3), 859-862.
3. Sanchez-Arago, M.; Chamorro, M.; Cuezva, J. M., Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis. 2010, 31(4), 567-576.
4. Wu, M.; Neilson, A.; Swift, A. L.; Moran, R.; Tamagnine, J.; Parslow, D.; Armistead, S.; Lemire, K.; Orrell, J.; Teich, J.; Chomicz, S.; Ferrick, D. A., Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am. J. Physiol. Cell Physiol., 2007, 292 (1), C125-36.
5. Lopez-Rios, F.; Sanchez-Arago, M.; Garcia-Garcia, E.; Ortega, A. D.; Berrendero, J. R.; Pozo-Rodriguez, F.; Lopez-Encuentra, A.; Ballestin, C.; Cuezva, J. M., Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res., 2007, 67 (19), 9013-9017.
6. Mazurek, S.; Grimm, H.; Boschek, C. B.; Vaupel, P.; Eigenbrodt, E., Pyruvate kinase type M2: a crossroad in the tumor metabolome. Br. J. Nutr., 2002, 87 (Suppl 1), S23-9.
7. Mazurek, S.; Eigenbrodt, E., The tumor metabolome. Anticancer Res. 2003, 23 (2A), 1149-1154.
8. Lupu, R.; Menendez, J. A., Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr. Pharm. Biotechnol., 2006, 7 (6), 483-493.
9. Swinnen, J. V.; Brusselmans, K.; Verhoeven, G., Increased lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Clin. Nutr. Metab. Care, 2006, 9 (4), 358-65.
10. Kuhajda, F. P., Fatty acid synthase and cancer: new application of an old pathway. Cancer Res., 2006, 66 (12), 5977-5980.
11. Kuhajda, F. P., AMP-activated protein kinase and human cancer: cancer metabolism revisited. Int. J. Obes. (Lond) 2008, 32 (Suppl. 4), S36-41.
12. Robey, R. B.; Hay, N., Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. oncogene, 2006, 25 (34), 4683-4696.
13. Shoshan-Barmatz, V.; Keinan, N.; Zaid, H., Uncovering the role of VDAC in the regulation of cell life and death. J. Bioenerg. Biomembr., 2008, 10, (3), 183-191.
14. Jones, R. G.; Plas, D. R.; Kubek, S.; Buzzai, M.; Mu, J.; Xu, Y.; Birnbaum, M. J.; Thompson, C. B., AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell, 2005, 18 (3), 283-293.
15. Okoshi, R.; Ozaki, T.; Yamamoto, H.; Ando, K.; Koida, N.; Ono, S.; Koda, T.; Kamijo, T.; Nakagawara, A.; Kizaki, H., Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J. Biol. Chem., 2008, 283 (7), 3979-3987.
16. Maiuri, M. C.; Tasdemir, E.; Criollo, A.; Morselli, E.; Vicencio, J. M.; Carnuccio, R.; Kroemer, G., Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ., 2009, 16 (1), 87-93.
17. Jin, S.; White, E., Role of autophagy in cancer: management of metabolic stress. Autophagy, 2007, 3 (1), 28-31.
18. Jin, S.; White, E., Tumor suppression by autophagy through the management of metabolic stress. Autophagy, 2008, 4 (5), 563-566.
19. Mohanti, B. K.; Rath, G. K.; Anantha, N.; Kannan, V.; Das, B. S.; Chandramouli, B. A.; Banerjee, A. K.; Das, S.; Jena, A.; Ravichandran, R.; Sahi, U. P.; Kumar, R.; Kapoor, N.; Kalia, V. K.; Dwarakanath, B. S.; Jain, V., Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int. J. Radiat Oncol. Biol. Phys., 1996, 35 (1), 103-111.
20. Singh, D.; Banerji, A. K.; Dwarakanath, B. S.; Tripathi, R. P.; Gupta, J. P.; Mathew, T. L.; Ravindranath, T.; Jain, V., Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol., 2005, 181 (8), 507-514.
21. Vijayaraghavan, R.; Kumar, D.; Dube, S. N.; Singh, R.; Pandey, K. S.; Bag, B. C.; Kaushik, M. P.; Sekhar, K.; Dwarakanath, B. S.; Ravindranath, T., Acute toxicity and cardio-respiratory effects of 2-deoxy-D-glucose: a promising radio sensitiser. Biomed. Environ. Sci., 2006, 19 (2), 96-103.
22. Zhu, Z.; Jiang, W.; McGinley, J. N.; Thompson, H. J., 2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. Cancer Res., 2005, 65 (15), 7023-7030.
23. Ihrlund, L. S.; Hernlund, E.; Khan, O.; Shoshan, M. C., 3-bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Molecular Oncology, 2008, 2, 94-101.
24. Hernlund, E.; Ihrlund, L. S.; Khan, O.; Ates, Y. O.; Linder, S.; Panaretakis, T.; Shoshan, M. C., Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int. J. Cancer, 2008, 123 (2), 476-483.
25. Ganapathy-Kanniappan, S.; Geschwind, J. F.; Kunjithapatham, R.; Buijs, M.; Syed, L. H.; Rao, P. P.; Ota, S.; Vali, M. The Pyruvic Acid Analog 3-Bromopyruvate Interferes With the Tetrazolium Reagent MTS in the Evaluation of Cytotoxicity. Assay Drug Dev. Technol., 2010, 8(2), 258-262.
26. Bruggisser, R.; von Daeniken, K.; Jundt, G.; Schaffner, W.; Tullberg-Reinert, H., Interference of plant extracts, phytoestrogens and antioxidants with the MTT tetrazolium assay. Planta Med., 2002, 68 (5), 445-448.
27. Lin, R. Z.; Chang, H. Y., Recent advances in three-dimensional multicellular spheroid culture for biomedical research. Biotechnol. J., 2008, 3 (9-10), 1172-1184.
28. Khaitan, D.; Chandna, S.; Arya, M. B.; Dwarakanath, B. S., Differential mechanisms of radiosensitization by 2-deoxy-Dglucose in the monolayers and multicellular spheroids of a human glioma cell line. Cancer Biol. Ther., 2006, 5 (9), 1142-1151.
29. Kaplan, O.; Navon, G.; Lyon, R. C.; Faustino, P. J.; Straka, E. J.; Cohen, J. S., Effects of 2-deoxyglucose on drug-sensitive and drugresistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism. Cancer Res., 1990, 50 (3), 544-551.
30. Haberkorn, U.; Morr, I.; Oberdorfer, F.; Bellemann, M. E.; Blatter, J.; Altmann, A.; Kahn, B.; van Kaick, G., Fluorodeoxyglucose uptake in vitro: aspects of method and effects of treatment with gemcitabine. J. Nucl. Med., 1994, 35 (11), 1842-1850.
31. Dwarakanath, B. S.; Jain, V. K., Enhancement of radiation damage by 2-deoxy-D-glucose in organ cultures of brain tumours. Indian J. Med. Res., 1985, 82, 266-268.
32. Dwarakanath, B. S.; Khaitan, D.; Ravindranath, T., 2-deoxy-D-glucose enhances the cytotoxicity of topoisomerase inhibitors in human tumor cell lines. Cancer Biol. Ther., 2004, 3 (9), 864-870.
33. Gupta, S.; Mathur, R.; Dwarakanath, B. S., The glycolytic inhibitor 2-deoxy-D-glucose enhances the efficacy of etoposide in ehrlich ascites tumor-bearing mice. Cancer Biol. Ther., 2005, 4 (1), 87-94.
34. Schefler, A. C.; Abramson, D. H., Retinoblastoma: what is new in 2007-2008. Curr. Opin. Ophthalmol., 2008, 19 (6), 526-534.
35. Maschek, G.; Savaraj, N.; Priebe, W.; Braunschweiger, P.; Hamilton, K.; Tidmarsh, G. F.; De Young, L. R.; Lampidis, T. J., 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res., 2004, 64 (1), 31-34.
36. Coleman, M. C.; Asbury, C. R.; Daniels, D.; Du, J.; Aykin-Burns, N.; Smith, B. J.; Li, L.; Spitz, D. R.; Cullen, J. J., 2-deoxy-Dglucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. Free Radic. Biol. Med., 2008, 44 (3), 322-331.
37. Simons, A. L.; Ahmad, I. M.; Mattson, D. M.; Dornfeld, K. J.; Spitz, D. R., 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res., 2007, 67 (7), 3364-3370.
38. Chatterjee, S.; Hirota, H.; Belfi, C. A.; Berger, S. J.; Berger, N. A., Hypersensitivity to DNA cross-linking agents associated with upregulation of glucose-regulated stress protein GRP78. Cancer Res., 1997, 57 (22), 5112-5116.
39. Tagg, S. L.; Foster, P. A.; Leese, M. P.; Potter, B. V.; Reed, M. J.; Purohit, A.; Newman, S. P., 2-Methoxyoestradiol-3,17-O,O-bissulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer. Br. J. Cancer, 2008, 99 (11), 1842-1848.
40. Pradelli, L. A.; Beneteau, M.; Chauvin, C.; Jacquin, M. A.; Marchetti, S.; Munoz-Pinedo, C.; Auberger, P.; Pende, M.; Ricci, J. E., Glycolysis inhibition sensitizes tumor cells to death receptorsinduced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene, 2009, 29(11), 1641-1652.
41. Hadzic, T.; Aykin-Burns, N.; Zhu, Y. Coleman, M. C.; Leick, K.; Jacobson, G. M.; Spitz, D. R., Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H(2)O(2)-mediated oxidative stress. Free Radic. Biol. Med., 2010, 48(8), 1024-1033.
42. Hernlund, E.; Hjerpe, E.; Avall-Lundqvist, E.; Shoshan, M., Ovarian carcinoma cells with low levels of beta-F1-ATPase are sensitive to combined platinum and 2-deoxy-D-glucose treatment. Mol. Cancer Ther., 2009, 8 (7), 1916-1923.
43. Holleman, A.; Cheok, M. H.; den Boer, M. L.; Yang, W.; Veerman, A. J.; Kazemier, K. M.; Pei, D.; Cheng, C.; Pui, C. H.; Relling, M. V.; Janka-Schaub, G. E.; Pieters, R.; Evans, W. E., Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med., 2004, 351 (6), 533-542.
44. Hulleman, E.; Kazemier, K. M.; Holleman, A.; VanderWeele, D. J.; Rudin, C. M.; Broekhuis, M. J.; Evans, W. E.; Pieters, R.; Den Boer, M. L., Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood, 2009, 113 (9), 2014-2021.
45. Jiang, W.; Zhu, Z.; Thompson, H. J., Modulation of the activities of AMP-activated protein kinase, protein kinase B, and mammalian target of rapamycin by limiting energy availability with 2-deoxyglucose. Mol. Carcinog., 2008, 47 (8), 616-628.
46. DiPaola, R. S.; Dvorzhinski, D.; Thalasila, A.; Garikapaty, V.; Doram, D.; May, M.; Bray, K.; Mathew, R.; Beaudoin, B.; Karp, C.; Stein, M.; Foran, D. J.; White, E., Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy. Prostate, 2008, 68 (16), 1743-1752.
47. Wu, H.; Zhu, H.; Liu, D. X.; Niu, T. K.; Ren, X.; Patel, R.; Hait, W. N.; Yang, J. M., Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy. Cancer Res., 2009, 69 (6), 2453-2460.
48. Wu, H.; Yang, J. M.; Jin, S.; Zhang, H.; Hait, W. N., Elongation factor-2 kinase regulates autophagy in human glioblastoma cells. Cancer Res., 2006, 66 (6), 3015-3023.
49. Zong, W. X.; Ditsworth, D.; Bauer, D. E.; Wang, Z. Q.; Thompson, C. B., Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes. Dev., 2004, 18 (11), 1272-1282.
50. Olivero, O. A.; Chang, P. K.; Lopez-Larraza, D. M.; Semino-Mora, M. C.; Poirier, M. C., Preferential formation and decreased removal of cisplatin-DNA adducts in Chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA. Mutat. Res., 1997, 391 (1-2), 79-86.
51. Yang, Z.; Schumaker, L. M.; Egorin, M. J.; Zuhowski, E. G.; Guo, Z.; Cullen, K. J., Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin. Cancer Res., 2006, 12 (19), 5817-5825.
52. Calvert, P.; Yao, K. S.; Hamilton, T. C.; O'Dwyer, P. J., Clinical studies of reversal of drug resistance based on glutathione. Chem. Biol. Interact, 1998, 111-112, 213-224.
53. Lin, X.; Zhang, F.; Bradbury, C. M.; Kaushal, A.; Li, L.; Spitz, D. R.; Aft, R. L.; Gius, D., 2-Deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res., 2003, 63 (12), 3413-3417.
54. Ahmad, I. M.; Aykin-Burns, N.; Sim, J. E.; Walsh, S. A.; Higashikubo, R.; Buettner, G. R.; Venkataraman, S.; Mackey, M. A.; Flanagan, S. W.; Oberley, L. W.; Spitz, D. R., Mitochondrial O2*- and H2O2 mediate glucose deprivation-induced stress in human cancer cells. J. Biol. Chem., 2005, 280 (6), 4254-4263.
55. Chen, Y.; Azad, M. B.; Gibson, S. B., Superoxide is the major reactive oxygen species regulating autophagy. Cell Death Differ., 2009, 16 (7), 1040-1052.
56. Azad, M. B.; Chen, Y.; Gibson, S. B., Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal., 2009, 11 (4), 777-790.
57. Aykin-Burns, N.; Ahmad, I. M.; Zhu, Y.; Oberley, L. W.; Spitz, D. R., Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem. J., 2009, 418 (1), 29-37.
58. Lynch, R. M.; Carrington, W.; Fogarty, K. E.; Fay, F. S., Metabolic modulation of hexokinase association with mitochondria in living smooth muscle cells. Am. J. Physiol., 1996, 270 (2 Pt 1), C488-499.
59. Heyfets, A.; Flescher, E., Cooperative cytotoxicity of methyl jasmonate with anti-cancer drugs and 2-deoxy-D-glucose. Cancer Lett., 2007, 250 (2), 300-310.
60. Kurtoglu, M.; Gao, N.; Shang, J.; Maher, J. C.; Lehrman, M. A.; Wangpaichitr, M.; Savaraj, N.; Lane, A. N.; Lampidis, T. J., Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with Nlinked glycosylation. Mol. Cancer Ther., 2007, 6 (11), 3049-3058.
61. Mandl, J.; Meszaros, T.; Banhegyi, G.; Hunyady, L.; Csala, M., Endoplasmic reticulum: nutrient sensor in physiology and pathology. Trends Endocrinol. Metab., 2009, 20 (4), 194-201.
62. Ko, Y. H.; Smith, B. L.; Wang, Y.; Pomper, M. G.; Rini, D. A.; Torbenson, M. S.; Hullihen, J.; Pedersen, P. L., Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem. Biophys. Res. Commun., 2004, 324 (1), 269-275.
63. Vali, M.; Vossen, J. A.; Buijs, M.; Engles, J. M.; Liapi, E.; Ventura, V. P.; Khwaja, A.; Acha-Ngwodo, O.; Shanmugasundaram, G.; Syed, L.; Wahl, R. L.; Geschwind, J. F., Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study. J. Pharmacol. Exp. Ther., 2008, 327 (1), 32-37.
64. Xu, R. H.; Pelicano, H.; Zhou, Y.; Carew, J. S.; Feng, L.; Bhalla, K. N.; Keating, M. J.; Huang, P., Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res., 2005, 65 (2), 613-621.
65. Zhang, X.; Varin, E.; Briand, M.; Allouche, S.; Heutte, N.; Schwartz, L.; Poulain, L.; Icard, P., Novel therapy for malignant pleural mesothelioma based on anti-energetic effect: an experimental study using 3-Bromopyruvate on nude mice. Anticancer Res., 2009, 29 (4), 1443-1448.
66. Cao, X.; Bloomston, M.; Zhang, T.; Frankel, W. L.; Jia, G.; Wang, B.; Hall, N. C.; Koch, R. M.; Cheng, H.; Knopp, M. V.; Sun, D., Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin. Cancer Res., 2008, 14 (6), 1831-1839.
67. Silverstein, R.; Lin, C. C.; Fanning, K. W.; Hung, B. T., Inactivation and modification of phosphoenolpyruvate carboxykinase differentially labeled with bromopyruvate. Biochim. Biophys. Acta., 1980, 614 (2), 534-544.
68. Pereira da Silva, A. P.; El-Bacha, T.; Kyaw, N.; dos Santos, R. S.; da-Silva, W. S.; Almeida, F. C.; Da Poian, A. T.; Galina, A., Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem. J., 2009, 417 (3), 717-726.
69. Ganapathy-Kanniappan, S.; Geschwind, J. F.; Kunjithapatham, R.; Buijs, M.; Vossen, J. A.; Tchernyshyov, I.; Cole, R. N.; Syed, L. H.; Rao, P. P.; Ota, S.; Vali, M., Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res., 2009, 29 (12), 4909-4918.
70. Chen, Z.; Zhang, H.; Lu, W.; Huang, P., Role of mitochondriaassociated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim. Biophys. Acta., 2009, 1787 (5), 553-560.
71. Mathupala, S. P.; Ko, Y. H.; Pedersen, P. L., Hexokinase-2 bound to mitochondria: cancer's stygian link to the Warburg Effect and a pivotal target for effective therapy. Semin. Cancer Biol., 2009, 19 (1), 17-24.
72. Dell'Antone, P., Inactivation of H+-vacuolar ATPase by the energy blocker 3-bromopyruvate, a new antitumour agent. Life Sci., 2006, 79 (21), 2049-2055.
73. Dell'Antone, P., Targets of 3-bromopyruvate, a new, energy depleting, anticancer agent. Med. Chem., 2009, 5 (6), 491-496.
74. Serkova, N.; Boros, L. G., Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications. Am. J. Pharmacogenomics, 2005, 5 (5), 293-302.
75. Gottschalk, S.; Anderson, N.; Hainz, C.; Eckhardt, S. G.; Serkova, N. J., Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin. Cancer Res., 2004, 10 (19), 6661-6668.
76. Klawitter, J.; Anderson, N.; Christians, U.; Leibfritz, D.; Eckhardt, S. G.; Serkova, N. J., Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study. Br. J. Cancer, 2009, 100 (6), 923-931.
77. Klawitter, J.; Kominsky, D. J.; Brown, J. L.; Christians, U.; Leibfritz, D.; Melo, J. V.; Eckhardt, S. G.; Serkova, N. J., Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br. J. Pharmacol., 2009, 158 (2), 588-600.
78. Skorta, I.; Oren, M.; Markwardt, C.; Gutekunst, M.; Aulitzky, W. E.; van der Kuip, H., Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity. Cancer Res., 2009, 69 (24), 9337-9345.
79. Bruce, I. A.; Slevin, N. J.; Homer, J. J.; McGown, A. T.; Ward, T. H., Synergistic effects of imatinib (STI 571) in combination with chemotherapeutic drugs in head and neck cancer. Anticancer Drugs, 2005, 16 (7), 719-726.
80. Sheu, L. F.; Young, Z. H.; Lee, W. C.; Chen, Y. F.; Kao, W. Y.; Chen, A., STI571 sensitizes nasopharyngeal carcinoma cells to cisplatin: sustained activation of ERK with improved growth inhibition. Int. J. Oncol., 2007, 30 (2), 403-411.
81. Sims, J. T.; Ganguly, S.; Fiore, L. S.; Holler, C. J.; Park, E. S.; Plattner, R., STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner. Biochem. Pharmacol., 2009, 78 (3), 249-260.
82. Avramis, I. A.; Laug, W. E.; Sausville, E. A.; Avramis, V. I., Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Cancer Chemother. Pharmacol., 2003, 52 (4), 307-718.
83. Ranza, E.; Bertolotti, A.; Facoetti, A.; Mariotti, L.; Pasi, F.; Ottolenghi, A.; Nano, R., Influence of imatinib mesylate on radiosensitivity of astrocytoma cells. Anticancer Res., 2009, 29 (11), 4575-4578.
84. Shingu, T.; Fujiwara, K.; Bogler, O.; Akiyama, Y.; Moritake, K.; Shinojima, N.; Tamada, Y.; Yokoyama, T.; Kondo, S., Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells. Int. J. Cancer, 2009, 124 (5), 1060-1071.
85. Corcoran, N. M.; Costello, A. J., Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer. BJU Int., 2005, 96 (4), 640-646.
86. Alberts, D. S.; Liu, P. Y.; Wilczynski, S. P.; Jang, A.; Moon, J.; Ward, J. H.; Beck, J. T.; Clouser, M.; Markman, M., Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int J Gynecol Cancer 2007, 17 (4), 784-788.
87. Coleman, R. L.; Broaddus, R. R.; Bodurka, D. C.; Wolf, J. K.; Burke, T. W.; Kavanagh, J. J.; Levenback, C. F.; Gershenson, D. M., Phase II trial of imatinib mesylate in patients with recurrent platinum-and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol. Oncol., 2006, 101 (1), 126-131.
88. Yardley, D. A.; Burris, H. A., 3rd; Markus, T.; Spigel, D. R.; Greco, F. A.; Mainwaring, M.; Waterhouse, D. M.; Webb, C. D.; Hainsworth, J. D., Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer. Clin. Breast Cancer, 2009, 9 (4), 237-242.
89. Gucluler, G.; Baran, Y., Docetaxel enhances the cytotoxic effects of imatinib on Philadelphia positive human chronic myeloid leukemia cells. Hematology, 2009, 14 (3), 139-144.
90. Williams, R. J.; Spencer, J. P.; Rice-Evans, C., Flavonoids: antioxidants or signalling molecules? Free Radic. Biol. Med., 2004, 36 (7), 838-849.
91. Crozier, A.; Jaganath, I. B.; Clifford, M. N., Dietary phenolics: chemistry, bioavailability and effects on health. Nat. Prod. Rep., 2009, 26 (8), 1001-1043.
92. Ramos, S., Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol. Nutr. Food Res., 2008, 52 (5), 507-526.
93. Silasi, D. A.; Alvero, A. B.; Rutherford, T. J.; Brown, D.; Mor, G., Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. Expert Opin Pharmacother., 2009, 10 (6), 1059-1067.
94. Cal, C.; Garban, H.; Jazirehi, A.; Yeh, C.; Mizutani, Y.; Bonavida, B., Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Curr. Med. Chem. Anticancer Agents 2003, 3 (2), 77-93.
95. Bishayee, A., Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res., (Phila Pa) 2009, 2 (5), 409-418.
96. Saiko, P.; Szakmary, A.; Jaeger, W.; Szekeres, T., Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat. Res., 2008, 658 (1-2), 68-94.
97. Kueck, A.; Opipari, A. W., Jr.; Griffith, K. A.; Tan, L.; Choi, M.; Huang, J.; Wahl, H.; Liu, J. R., Resveratrol inhibits glucose metabolism in human ovarian cancer cells. Gynecol. Oncol., 2007, 107 (3), 450-457.
98. Puissant, A.; Robert, G.; Fenouille, N.; Luciano, F.; Cassuto, J. P.; Raynaud, S.; Auberger, P., Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res., 2010, 70 (3), 1042-1052.
99. Baatout, S.; Derradji, H.; Jacquet, P.; Ooms, D.; Michaux, A.; Mergeay, M., Enhanced radiation-induced apoptosis of cancer cell lines after treatment with resveratrol. Int. J. Mol. Med., 2004, 13 (6), 895-902.
100. Baatout, S.; Derradji, H.; Jacquet, P.; Mergeay, M., Increased radiation sensitivity of an eosinophilic cell line following treatment with epigallocatechin-gallate, resveratrol and curcuma. Int. J. Mol. Med., 2005, 15 (2), 337-52.
101. Scarlatti, F.; Sala, G.; Ricci, C.; Maioli, C.; Milani, F.; Minella, M.; Botturi, M.; Ghidoni, R., Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett., 2007, 253 (1), 124-130.
102. Lu, K. H.; Chen, Y. W.; Tsai, P. H.; Tsai, M. L.; Lee, Y. Y.; Chiang, C. Y.; Kao, C. L.; Chiou, S. H.; Ku, H. H.; Lin, C. H.; Chen, Y. J., Evaluation of radiotherapy effect in resveratrol-treated medulloblastoma cancer stem-like cells. Childs Nerv. Syst., 2009, 25 (5), 543-550.
103. Carsten, R. E.; Bachand, A. M.; Bailey, S. M.; Ullrich, R. L., Resveratrol reduces radiation-induced chromosome aberration frequencies in mouse bone marrow cells. Radiat Res., 2008, 169 (6), 633-638.
104. Beher, D.; Wu, J.; Cumine, S.; Kim, K. W.; Lu, S. C.; Atangan, L.; Wang, M., Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des., 2009, 74 (6), 619-624.
105. Horvath, Z.; Saiko, P.; Illmer, C.; Madlener, S.; Hoechtl, T.; Bauer, W.; Erker, T.; Jaeger, W.; Fritzer-Szekeres, M.; Szekeres, T., Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Exp. Hematol., 2005, 33 (3), 329-335.
106. Fritzer-Szekeres, M.; Savinc, I.; Horvath, Z.; Saiko, P.; Pemberger, M.; Graser, G.; Bernhaus, A.; Ozsvar-Kozma, M.; Grusch, M.; Jaeger, W.; Szekeres, T., Biochemical effects of piceatannol in human HL-60 promyelocytic leukemia cells--synergism with Ara-C. Int. J. Oncol., 2008, 33 (4), 887-892.
107. Javvadi, P.; Segan, A. T.; Tuttle, S. W.; Koumenis, C., The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol. Pharmacol., 2008, 73 (5), 1491-1501.
108. Yang, K. C.; Tsai, C. Y.; Wang, Y. J.; Wei, P. L.; Lee, C. H.; Chen, J. H.; Wu, C. H.; Ho, Y. S., Apple polyphenol phloretin potentiates the anticancer actions of paclitaxel through induction of apoptosis in human hep G2 cells. Mol. Carcinog., 2009, 48 (5), 420-431.
109. Bhosle, S. M.; Huilgol, N. G.; Mishra, K. P., Enhancement of radiation-induced oxidative stress and cytotoxicity in tumor cells by ellagic acid. Clin. Chim. Acta., 2005, 359 (1-2), 89-100.
110. Hail, N., Jr.; Cortes, M.; Drake, E. N.; Spallholz, J. E., Cancer chemoprevention: a radical perspective. Free Radic. Biol. Med., 2008, 45 (2), 97-110.
111. Zessner, H.; Pan, L.; Will, F.; Klimo, K.; Knauft, J.; Niewohner, R.; Hummer, W.; Owen, R.; Richling, E.; Frank, N.; Schreier, P.; Becker, H.; Gerhauser, C., Fractionation of polyphenol-enriched apple juice extracts to identify constituents with cancer chemopreventive potential. Mol. Nutr. Food Res., 2008, 52 (Suppl 1), S28-44.
112. Zhang, S.; Morris, M. E., Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Ther., 2003, 304 (3), 1258-1267.
113. Verkman, A. S.; Hara-Chikuma, M.; Papadopoulos, M. C., Aquaporins--new players in cancer biology. J. Mol. Med., 2008, 86 (5), 523-529.
114. Kim, M. S.; Kwon, J. Y.; Kang, N. J.; Lee, K. W.; Lee, H. J., Phloretin induces apoptosis in H-Ras MCF10A human breast tumor cells through the activation of p53 via JNK and p38 mitogenactivated protein kinase signaling. Ann. N. Y. Acad. Sci., 2009, 1171, 479-483.
115. Ligeret, H.; Barthelemy, S.; Zini, R.; Tillement, J. P.; Labidalle, S.; Morin, D., Effects of curcumin and curcumin derivatives on mitochondrial permeability transition pore. Free Radic. Biol. Med., 2004, 36 (7), 919-929.
116. Yallapu, M. M.; Maher, D. M.; Sundram, V.; Bell, M. C.; Jaggi, M.; Chauhan, S. C., Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J. Ovarian Res., 2010, 3, 11.
117. Bansal, T.; Jaggi, M.; Khar, R. K.; Talegaonkar, S., Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J. Pharm. Pharm. Sci., 2009, 12 (1), 46-78.
118. Hersey, P.; Watts, R. N.; Zhang, X. D.; Hackett, J., Metabolic approaches to treatment of melanoma. Clin. Cancer Res., 2009, 15 (21), 6490-6494.
119. Fantin, V. R.; St-Pierre, J.; Leder, P., Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 2006, 9 (6), 425-434.
120. Le, A.; Cooper, C. R.; Gouw, A. M.; Dinavahi, R.; Maitra, A.; Deck, L. M.; Royer, R. E.; Vander Jagt, D. L.; Semenza, G. L.; Dang, C. V., Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad Sci. USA., 2010, 107 (5), 2037-2042.
121. Fang, J.; Quinones, Q. J.; Holman, T. L.; Morowitz, M. J.; Wang, Q.; Zhao, H.; Sivo, F.; Maris, J. M.; Wahl, M. L., The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol. Pharmacol., 2006, 70 (6), 2108-2115.
122. Sonveaux, P.; Vegran, F.; Schroeder, T.; Wergin, M. C.; Verrax, J.; Rabbani, Z. N.; De Saedeleer, C. J.; Kennedy, K. M.; Diepart, C.; Jordan, B. F.; Kelley, M. J.; Gallez, B.; Wahl, M. L.; Feron, O.; Dewhirst, M. W., Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest., 2008, 118 (12), 3930-3942.
123. Cao, W.; Yacoub, S.; Shiverick, K. T.; Namiki, K.; Sakai, Y.; Porvasnik, S.; Urbanek, C.; Rosser, C. J., Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate, 2008, 68 (11), 1223-1231.
124. Dhar, S.; Lippard, S. J., Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. Proc. Natl. Acad. Sci. USA., 2009, 106 (52), 22199-22204.
125. Wenzel, U.; Nickel, A.; Daniel, H., alpha-Lipoic acid induces apoptosis in human colon cancer cells by increasing mitochondrial respiration with a concomitant O2-*-generation. Apoptosis, 2005, 10 (2), 359-368.
126. Schwartz, L.; Abolhassani, M.; Guais, A.; Sanders, E.; Steyaert, J. M.; Campion, F.; Israel, M., A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results. Oncol. Rep., 2010, 23 (5), 1407-1416.
127. Rasbach, K. A.; Schnellmann, R. G., Isoflavones promote mitochondrial biogenesis. J. Pharmacol. Exp. Ther., 2008, 325 (2), 536-543.
128. Michelakis, E. D.; Webster, L.; Mackey, J. R., Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br. J. Cancer, 2008, 99 (7), 989-994.
129. Hu, W.; Zhang, C.; Wu, R.; Sun, Y.; Levine, A.; Feng, Z., Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl. Acad. Sci. USA., 2010, 107(16), 7455-7460.
130. Wise, D. R.; DeBerardinis, R. J.; Mancuso, A.; Sayed, N.; Zhang, X. Y.; Pfeiffer, H. K.; Nissim, I.; Daikhin, E.; Yudkoff, M.; McMahon, S. B.; Thompson, C. B., Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. USA., 2008, 105 (48), 18782-18787.
131. Gao, P.; Tchernyshyov, I.; Chang, T. C.; Lee, Y. S.; Kita, K.; Ochi, T.; Zeller, K. I.; De Marzo, A. M.; Van Eyk, J. E.; Mendell, J. T.; Dang, C. V., c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature, 2009, 458 (7239), 762-765.
132. Garrido, N.; Perez-Martos, A.; Faro, M.; Lou-Bonafonte, J. M.; Fernandez-Silva, P.; Lopez-Perez, M. J.; Montoya, J.; Enriquez, J. A., Cisplatin-mediated impairment of mitochondrial DNA metabolism inversely correlates with glutathione levels. Biochem J 2008, 414 (1), 93-102.
133. Bianchi, N. O.; Bianchi, M. S.; Richard, S. M., Mitochondrial genome instability in human cancers. Mutat. Res., 2001, 488 (1), 9-23.
134. Neuzil, J.; Dyason, J. C.; Freeman, R.; Dong, L. F.; Prochazka, L.; Wang, X. F.; Scheffler, I.; Ralph, S. J., Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II. J. Bioenerg. Biomembr., 2007, 39 (1), 65-72.
135. Pelicano, H.; Feng, L.; Zhou, Y.; Carew, J. S.; Hileman, E. O.; Plunkett, W.; Keating, M. J.; Huang, P., Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem., 2003, 278 (39), 37832-37839.
136. Ota, S.; Horigome, K.; Ishii, T.; Nakai, M.; Hayashi, K.; Kawamura, T.; Kishino, A.; Taiji, M.; Kimura, T., Metformin suppresses glucose-6-phosphatase expression by a complex I inhibition and AMPK activation-independent mechanism. Biochem. Biophys. Res. Commun., 2009, 388 (2), 311-316.
137. Ben Sahra, I.; Laurent, K.; Giuliano, S.; Larbret, F.; Ponzio, G.; Gounon, P.; Le Marchand-Brustel, Y.; Giorgetti-Peraldi, S.; Cormont, M.; Bertolotto, C.; Deckert, M.; Auberger, P.; Tanti, J. F.; Bost, F., Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res., 2010, 70 (6), 2465-2475.
138. Buzzai, M.; Jones, R. G.; Amaravadi, R. K.; Lum, J. J.; DeBerardinis, R. J.; Zhao, F.; Viollet, B.; Thompson, C. B., Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res., 2007, 67 (14), 6745-6752.
139. Filomeni, G.; Desideri, E.; Cardaci, S.; Graziani, I.; Piccirillo, S.; Rotilio, G.; Ciriolo, M. R., Carcinoma cells activate AMP-activated protein kinase-dependent autophagy as survival response to kaempferol-mediated energetic impairment. Autophagy, 2010, 6 (2).
140. Pollard, P. J.; Briere, J. J.; Alam, N. A.; Barwell, J.; Barclay, E.; Wortham, N. C.; Hunt, T.; Mitchell, M.; Olpin, S.; Moat, S. J.; Hargreaves, I. P.; Heales, S. J.; Chung, Y. L.; Griffiths, J. R.; Dalgleish, A.; McGrath, J. A.; Gleeson, M. J.; Hodgson, S. V.; Poulsom, R.; Rustin, P.; Tomlinson, I. P., Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet., 2005, 14 (15), 2231-2239.
141. Dong, L. F.; Low, P.; Dyason, J. C.; Wang, X. F.; Prochazka, L.; Witting, P. K.; Freeman, R.; Swettenham, E.; Valis, K.; Liu, J.; Zobalova, R.; Turanek, J.; Spitz, D. R.; Domann, F. E.; Scheffler, I. E.; Ralph, S. J.; Neuzil, J., Alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene, 2008, 27 (31), 4324-4335.
142. Dong, L. F.; Freeman, R.; Liu, J.; Zobalova, R.; Marin-Hernandez, A.; Stantic, M.; Rohlena, J.; Valis, K.; Rodriguez-Enriquez, S.; Butcher, B.; Goodwin, J.; Brunk, U. T.; Witting, P. K.; Moreno-Sanchez, R.; Scheffler, I. E.; Ralph, S. J.; Neuzil, J., Suppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II. Clin. Cancer Res., 2009, 15 (5), 1593-1600.
143. Lim, S. J.; Lee, Y. J.; Park, D. H.; Lee, E.; Choi, M. K.; Park, W.; Chun, K. H.; Choi, H. G.; Cho, J. S., Alpha-tocopheryl succinate sensitizes human colon cancer cells to exisulind-induced apoptosis. Apoptosis, 2007, 12 (2), 423-431.
144. Lim, S. J.; Choi, M. K.; Kim, M. J.; Kim, J. K., Alpha-tocopheryl succinate potentiates the paclitaxel-induced apoptosis through enforced caspase 8 activation in human H460 lung cancer cells. Exp. Mol. Med., 2009, 41 (10), 737-745.
145. Kanai, K.; Kikuchi, E.; Mikami, S.; Suzuki, E.; Uchida, Y.; Kodaira, K.; Miyajima, A.; Ohigashi, T.; Nakashima, J.; Oya, M., Vitamin E succinate induced apoptosis and enhanced chemosensitivity to paclitaxel in human bladder cancer cells in vitro and in vivo. Cancer Sci., 2010, 101 (1), 216-223.
146. Cuperus, R.; Leen, R.; Tytgat, G. A.; Caron, H. N.; van Kuilenburg, A. B., Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma. Cell Mol. Life Sci., 2010, 67 (5), 807-816.
147. Zhu, G.; Cao, X.; Chang, J. Y.; Milas, L.; Wallace, S.; Li, C., Polymeric retinoid prodrug PG-4HPR enhances the radiation response of lung cancer. Oncol. Rep., 2007, 18 (3), 645-651.
148. Stockl, P.; Hutter, E.; Zwerschke, W.; Jansen-Durr, P., Sustained inhibition of oxidative phosphorylation impairs cell proliferation and induces premature senescence in human fibroblasts. Exp. Gerontol., 2006, 41 (7), 674-682.
149. Klimova, T.; Chandel, N. S., Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ., 2008, 15 (4), 660-666.
150. Xiao, D.; Powolny, A. A.; Singh, S. V., Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger reactive oxygen species-dependent apoptosis in human breast cancer cells. J. Biol. Chem., 2008, 283 (44), 30151-30163.
151. Prakash Sahu, R.; Epperly, M. W.; Srivastava, S. K., Benzyl isothiocyanate sensitizes human pancreatic cancer cells to radiation therapy. Front Biosci., (Elite Ed) 2009, 1, 568-576.
152. Willers, I. M.; Isidoro, A.; Ortega, A. D.; Fernandez, P. L.; Cuezva, J. M., Selective inhibition of beta-F1-ATPase mRNA translation in human tumours. Biochem. J., 2010, 426 (3), 319-326.
153. Green, R. C.; Thumser, A. E.; Povey, D.; Saldanha, J. W.; Potter, B. S.; Palmer, R. A.; Howlin, B. J., A comparative study of the single crystal X-ray determination and molecular modelling of the binding of oligomycin to ATP synthase. Comput. Biol. Chem., 2009, 33 (3), 189-195.
154. Hao, W.; Chang, C. P.; Tsao, C. C.; Xu, J., Oligomycin-induced bioenergetic adaptation in cancer cells with heterogeneous bioenergetic organization. J. Biol. Chem., 2010.
155. Zheng, J.; Ramirez, V. D., Piceatannol, a stilbene phytochemical, inhibits mitochondrial F0F1-ATPase activity by targeting the F1 complex. Biochem. Biophys. Res. Commun., 1999, 261 (2), 499-503.
156. Lim, H. W.; Lim, H. Y.; Wong, K. P., Uncoupling of oxidative phosphorylation by curcumin: implication of its cellular mechanism of action. Biochem. Biophys. Res. Commun., 2009, 389 (1), 187-192.
157. Gledhill, J. R.; Montgomery, M. G.; Leslie, A. G.; Walker, J. E., Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc. Natl. Acad. Sci. USA., 2007, 104 (34), 13632-13637.
158. Danial, N. N., BAD: undertaker by night, candyman by day. Oncogene, 2008, 27 (Suppl.,) 1, S53-70.
159. Floridi, A.; D'Atri, S.; Menichini, R.; Marcante, M. L.; Nista, A.; Silvestrini, B.; Caputo, A.; De Martino, C., The effect of the association of Gossypol and Lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Exp. Mol. Pathol., 1983, 38 (3), 322-335.
160. Kang, M. H.; Reynolds, C. P., Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res., 2009, 15 (4), 1126-1132.
161. Meng, Y.; Tang, W.; Dai, Y.; Wu, X.; Liu, M.; Ji, Q.; Ji, M.; Pienta, K.; Lawrence, T.; Xu, L., Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol. Cancer Ther., 2008, 7 (7), 2192-2202.
162. Paoluzzi, L.; Gonen, M.; Gardner, J. R.; Mastrella, J.; Yang, D.; Holmlund, J.; Sorensen, M.; Leopold, L.; Manova, K.; Marcucci, G.; Heaney, M. L.; O'Connor, O. A., Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood, 2008, 111 (11), 5350-5358.
163. Zerp, S. F.; Stoter, R.; Kuipers, G.; Yang, D.; Lippman, M. E.; van Blitterswijk, W. J.; Bartelink, H.; Rooswinkel, R.; Lafleur, V.; Verheij, M., AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis. Radiat. Oncol., 2009, 4, 47.
164. Shiau, C. W.; Huang, J. W.; Wang, D. S.; Weng, J. R.; Yang, C. C.; Lin, C. H.; Li, C.; Chen, C. S., alpha-Tocopheryl succinate induces apoptosis in prostate cancer cells in part through inhibition of BclxL/ Bcl-2 function. J. Biol. Chem., 2006, 281 (17), 11819-11825.
165. Fulda, S., Betulinic acid: a natural product with anticancer activity. Mol. Nutr. Food Res., 2009, 53 (1), 140-146.
166. Mullauer, F. B.; Kessler, J. H.; Medema, J. P., Betulinic acid, a natural compound with potent anticancer effects. Anticancer Drugs 2010, 21 (3), 215-227.
167. Ravagnan, L.; Marzo, I.; Costantini, P.; Susin, S. A.; Zamzami, N.; Petit, P. X.; Hirsch, F.; Goulbern, M.; Poupon, M. F.; Miccoli, L.; Xie, Z.; Reed, J. C.; Kroemer, G., Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene, 1999, 18 (16), 2537-2546.
168. Selzer, E.; Pimentel, E.; Wacheck, V.; Schlegel, W.; Pehamberger, H.; Jansen, B.; Kodym, R., Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J. Invest Dermatol., 2000, 114 (5), 935-940.
169. Yamai, H.; Sawada, N.; Yoshida, T.; Seike, J.; Takizawa, H.; Kenzaki, K.; Miyoshi, T.; Kondo, K.; Bando, Y.; Ohnishi, Y.; Tangoku, A., Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo. Int. J. Cancer, 2009, 125 (4), 952-960.
170. Fulda, S.; Debatin, K. M., Sensitization for anticancer drug-induced apoptosis by betulinic Acid. Neoplasia, 2005, 7 (2), 162-170.
171. De Lena, M.; Lorusso, V.; Bottalico, C.; Brandi, M.; De Mitrio, A.; Catino, A.; Guida, M.; Latorre, A.; Leone, B.; Vallejo, C.; Gargano, G., Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum. J. Clin. Oncol., 1997, 15 (10), 3208-3213.
172. Gebbia, V.; Borsellino, N.; Testa, A.; Latteri, M. A.; Milia, V.; Valdesi, M.; Giotta, F.; Gebbia, N.; Colucci, G., Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM). Anticancer Drugs, 1997, 8 (10), 943-948.
173. Klinge, C. M., Estrogenic control of mitochondrial function and biogenesis. J. Cell Biochem., 2008, 105 (6), 1342-1351.
174. Suetsugi, M.; Su, L.; Karlsberg, K.; Yuan, Y. C.; Chen, S., Flavone and isoflavone phytoestrogens are agonists of estrogenrelated receptors. Mol Cancer Res 2003, 1 (13), 981-91.
175. Harris, D. M.; Besselink, E.; Henning, S. M.; Go, V. L.; Heber, D., Phytoestrogens induce differential estrogen receptor alpha-or Betamediated responses in transfected breast cancer cells. Exp. Biol. Med., (Maywood) 2005, 230 (8), 558-568.
176. Renehan, A. G.; Frystyk, J.; Flyvbjerg, A., Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol. Metab., 2006, 17 (8), 328-336.
177. Brown, K. A.; Simpson, E. R., Obesity and breast cancer: progress to understanding the relationship. Cancer Res., 2010, 70 (1), 4-7.
178. Hsu, I. R.; Kim, S. P.; Kabir, M.; Bergman, R. N., Metabolic syndrome, hyperinsulinemia, and cancer. Am. J. Clin. Nutr., 2007, 86 (3), s867-71.
179. Marshall, S., Role of insulin, adipocyte hormones, and nutrientsensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer. Sci. STKE, 2006, 2006 (346), re7.
180. Hocman, G., Prevention of cancer: restriction of nutritional energy intake (joules). Comp. Biochem. Physiol. A Comp. Physiol., 1988, 91 (2), 209-220.
181. Shima, N.; Swiger, R. R.; Heddle, J. A., Dietary restriction during murine development provides protection against MNU-induced mutations. Mutat. Res., 2000, 470 (2), 189-200.
182. Silverman, J.; Powers, J.; Stromberg, P.; Pultz, J. A.; Kent, S., Effects on C3H mouse mammary cancer of changing from a high fat to a low fat diet before, at, or after puberty. Cancer Res., 1989, 49 (14), 3857-3860.
183. Ong, K. R.; Sims, A. H.; Harvie, M.; Chapman, M.; Dunn, W. B.; Broadhurst, D.; Goodacre, R.; Wilson, M.; Thomas, N.; Clarke, R. B.; Howell, A., Biomarkers of dietary energy restriction in women at increased risk of breast cancer. Cancer Prev. Res. (Phila Pa) 2009, 2 (8), 720-731.
184. Thompson, H. J.; Zhu, Z.; Jiang, W., Dietary energy restriction in breast cancer prevention. J. Mammary Gland Biol. Neoplasia, 2003, 8 (1), 133-142.
185. Bruchim, I.; Attias, Z.; Werner, H., Targeting the IGF1 axis in cancer proliferation. Expert Opin. Ther. Targets, 2009, 13 (10), 1179-1192.
186. Holvoet, P., Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh. K. Acad. Geneeskd Belg., 2008, 70 (3), 193-219.
187. Misra, P., AMP activated protein kinase: a next generation target for total metabolic control. Expert Opin. Ther. Targets, 2008, 12 (1), 91-100.
188. Lage, R.; Dieguez, C.; Vidal-Puig, A.; Lopez, M., AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol. Med., 2008, 14 (12), 539-549.
189. Menendez, J. A.; Vazquez-Martin, A.; Ortega, F. J.; Fernandez-Real, J. M., Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer. Clin. Chem., 2009, 55 (3), 425-438.
190. Vazquez-Martin, A.; Colomer, R.; Brunet, J.; Menendez, J. A., Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Int. J. Oncol., 2007, 31 (4), 769-776.
191. Grunt, T. W.; Wagner, R.; Grusch, M.; Berger, W.; Singer, C. F.; Marian, B.; Zielinski, C. C.; Lupu, R., Interaction between fatty acid synthase-and ErbB-systems in ovarian cancer cells. Biochem. Biophys. Res. Commun., 2009, 385 (3), 454-459.
192. Menendez, J. A.; Lupu, R.; Colomer, R., Inhibition of tumorassociated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER-2/ neu-overexpressing human breast cancer cells to docetaxel (taxotere). Breast Cancer Res Treat 2004, 84 (2), 183-195.
193. Vazquez-Martin, A.; Ropero, S.; Brunet, J.; Colomer, R.; Menendez, J. A., Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. Oncol. Rep., 2007, 18 (4), 973-980.
194. Okawa, Y.; Hideshima, T.; Ikeda, H.; Raje, N.; Vallet, S.; Kiziltepe, T.; Yasui, H.; Enatsu, S.; Pozzi, S.; Breitkreutz, I.; Cirstea, D.; Santo, L.; Richardson, P.; Anderson, K. C., Fatty acid synthase is a novel therapeutic target in multiple myeloma. Br. J. Haematol., 2008, 141 (5), 659-671.
195. Brusselmans, K.; De Schrijver, E.; Heyns, W.; Verhoeven, G.; Swinnen, J. V., Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int. J. Cancer, 2003, 106 (6), 856-862.
196. Puig, T.; Turrado, C.; Benhamu, B.; Aguilar, H.; Relat, J.; Ortega-Gutierrez, S.; Casals, G.; Marrero, P. F.; Urruticoechea, A.; Haro, D.; Lopez-Rodriguez, M. L.; Colomer, R., Novel Inhibitors of Fatty Acid Synthase with Anticancer Activity. Clin. Cancer Res., 2009, 15 (24), 7608-7615.
197. Kridel, S. J.; Axelrod, F.; Rozenkrantz, N.; Smith, J. W., Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res., 2004, 64 (6), 2070-2075.
198. Carvalho, M. A.; Zecchin, K. G.; Seguin, F.; Bastos, D. C.; Agostini, M.; Rangel, A. L.; Veiga, S. S.; Raposo, H. F.; Oliveira, H. C.; Loda, M.; Coletta, R. D.; Graner, E., Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. Int. J. Cancer, 2008, 123 (11), 2557-2565.
199. Dowling, S.; Cox, J.; Cenedella, R. J., Inhibition of fatty acid synthase by Orlistat accelerates gastric tumor cell apoptosis in culture and increases survival rates in gastric tumor bearing mice in vivo. Lipids 2009, 44 (6), 489-498.
200. Martinez-Villaluenga, C.; Rupasinghe, S. G.; Schuler, M. A.; Gonzalez de Mejia, E., Peptides from purified soybean betaconglycinin inhibit fatty acid synthase by interaction with the thioesterase catalytic domain. FEBS. J., 2010, 277 (6), 1481-1493.
201. Bauer, D. E.; Hatzivassiliou, G.; Zhao, F.; Andreadis, C.; Thompson, C. B., ATP citrate lyase is an important component of cell growth and transformation. Oncogene, 2005, 24 (41), 6314-6322.
202. Migita, T.; Narita, T.; Nomura, K.; Miyagi, E.; Inazuka, F.; Matsuura, M.; Ushijima, M.; Mashima, T.; Seimiya, H.; Satoh, Y.; Okumura, S.; Nakagawa, K.; Ishikawa, Y., ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res., 2008, 68 (20), 8547-8554.
203. Hatzivassiliou, G.; Zhao, F.; Bauer, D. E.; Andreadis, C.; Shaw, A. N.; Dhanak, D.; Hingorani, S. R.; Tuveson, D. A.; Thompson, C. B., ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell, 2005, 8 (4), 311-321.
204. Holubarsch, C. J.; Rohrbach, M.; Karrasch, M.; Boehm, E.; Polonski, L.; Ponikowski, P.; Rhein, S., A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin. Sci., (Lond) 2007, 113 (4), 205-212.
205. Samudio, I.; Harmancey, R.; Fiegl, M.; Kantarjian, H.; Konopleva, M.; Korchin, B.; Kaluarachchi, K.; Bornmann, W.; Duvvuri, S.; Taegtmeyer, H.; Andreeff, M., Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J. Clin. Invest., 2010, 120 (1), 142-156.
206. Liu, Y., Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis., 2006, 9 (3), 230-234.
207. Fredenrich, A.; Grimaldi, P. A., PPAR delta: an uncompletely known nuclear receptor. Diabetes Metab., 2005, 31 (1), 23-27.
208. Turturro, F.; Oliver, R., 3rd; Friday, E.; Nissim, I.; Welbourne, T., Troglitazone and pioglitazone interactions via PPAR-gammaindependent and-dependent pathways in regulating physiological responses in renal tubule-derived cell lines. Am. J. Physiol. Cell Physiol., 2007, 292 (3), C1137-1146.
209. Wei, S.; Kulp, S. K.; Chen, C. S., Energy restriction as an antitumor target of thiazolidinediones. J. Biol. Chem., 2010.
210. Akasaki, Y.; Liu, G.; Matundan, H. H.; Ng, H.; Yuan, X.; Zeng, Z.; Black, K. L.; Yu, J. S., A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and-9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells. J. Biol. Chem., 2006, 281 (10), 6165-6174.
211. Gu, C.; Ye, T.; Wells, R. A., Synergistic effects of troglitazone in combination with cytotoxic agents in acute myelogenous leukaemia cells. Leuk Res., 2006, 30 (11), 1447-1451.
212. Grund, K.; Ahmadi, R.; Jung, F.; Funke, V.; Gdynia, G.; Benner, A.; Sykora, J.; Walczak, H.; Joos, S.; Felsberg, J.; Reifenberger, G.; Wiestler, O. D.; Herold-Mende, C.; Roth, W., Troglitazone-mediated sensitization to TRAIL-induced apoptosis is regulated by proteasome-dependent degradation of FLIP and ERK1/2-dependent phosphorylation of BAD. Cancer Biol. Ther., 2008, 7 (12), 1982-1990.
213. Schultze, K.; Bock, B.; Eckert, A.; Oevermann, L.; Ramacher, D.; Wiestler, O.; Roth, W., Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis, 2006, 11 (9), 1503-1512.
214. Copland, J. A.; Marlow, L. A.; Kurakata, S.; Fujiwara, K.; Wong, A. K.; Kreinest, P. A.; Williams, S. F.; Haugen, B. R.; Klopper, J. P.; Smallridge, R. C., Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene, 2006, 25 (16), 2304-2317.
215. Algire, C.; Amrein, L.; Zakikhani, M.; Panasci, L.; Pollak, M., Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr. Relat. Cancer, 2010, 17 (2), 351-360.
216. Rattan, R.; Giri, S.; Hartmann, L.; Shridhar, V., Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J. Cell Mol. Med., 2009.
217. Gotlieb, W. H.; Saumet, J.; Beauchamp, M. C.; Gu, J.; Lau, S.; Pollak, M. N.; Bruchim, I., In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol. Oncol., 2008, 110 (2), 246-250.
218. Lopez-Lazaro, M.; Willmore, E.; Austin, C. A., The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells. Mutat Res., 2010, 696 (1), 41-47.
219. Sarkar, F. H.; Li, Y.; Wang, Z.; Padhye, S., Lesson Learned from Nature for the Development of Novel Anti-Cancer Agents: Implication of Isoflavone, Curcumin, and their Synthetic Analogs. Curr. Pharm. Des., 2010.
220. Chen, X.; Tang, L. J.; Sun, Y. N.; Qiu, P. H.; Liang, G., Syntheses, characterization and antitumor activities of transition metal complexes with isoflavone. J. Inorg. Biochem., 2010, 104 (4), 379-384.
221. Leonarduzzi, G.; Testa, G.; Sottero, B.; Gamba, P.; Poli, G., Design and development of nanovehicle-based delivery systems for preventive or therapeutic supplementation with flavonoids. Curr. Med. Chem., 2010, 17 (1), 74-95.
222. Falsaperla, M.; Morgia, G.; Tartarone, A.; Ardito, R.; Romano, G., Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. Eur. Urol., 2005, 47 (4), 449-454; discussion 454-5.
223. Yuce, A.; Atessahin, A.; Ceribasi, A. O.; Aksakal, M., Ellagic acid prevents cisplatin-induced oxidative stress in liver and heart tissue of rats. Basic Clin. Pharmacol. Toxicol., 2007, 101 (5), 345-249.
224. Smolkova, K.; Plecita-Hlavata, L.; Bellance, N.; Benard, G.; Rossignol, R.; Jezek, P., Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. Int. J. Biochem. Cell Biol., 2010.